Insilico Medicine (“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, and TaiGen Biotechnology, a listed discovery-based and market-focused pharmaceutical company, as well as TaiGen Biopharmaceuticals, its wholly-owned Beijing subsidiary (both referred to as “TaiGen”), today announced an exclusive pipeline out-licensing collaboration.